Radiopharma

🎉 We're celebrating a 𝘆𝗲𝗮𝗿 𝗳𝘂𝗹𝗹 𝗼𝗳 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 and are looking ahead to a 𝗯𝗿𝗶𝗴𝗵𝘁 𝗳𝘂𝘁𝘂𝗿𝗲 🌟 As we close the chapter on an 𝗲𝘅𝗰𝗲𝗽𝘁𝗶𝗼𝗻𝗮𝗹 𝘆𝗲𝗮𝗿, Dr. Harald Hasselmann, our CEO shares a 𝘀𝗽𝗲𝗰𝗶𝗮𝗹  𝗺𝗲𝘀𝘀𝗮𝗴𝗲 𝗳𝗼𝗿 𝗼𝘂𝗿 𝘃𝗮𝗹𝘂𝗲𝗱 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆. 🎥 🎄 With the holiday season upon us, we want to take a moment to express our 𝗱𝗲𝗲𝗽 𝗴𝗿𝗮𝘁𝗶𝘁𝘂𝗱𝗲 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘁𝗿𝘂𝘀𝘁 𝗮𝗻𝗱 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻. Your support fuels our mission to 𝗺𝗮𝗸𝗲 𝗮 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in nuclear medicine, radiation therapy and isotope production. ⚛️ 🥂Here's to a New Year filled with 𝗴𝗿𝗼𝘄𝘁𝗵, 𝘀𝗵𝗮𝗿𝗲𝗱 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗺𝗲𝗻𝘁𝘀, 𝗮𝗻𝗱 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀! 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 for being part of this exciting journey. 👏 #SeasonsGreetings #NewYear #ThankYou #ContributingToSavingLives  

👉 𝗦𝗶𝗺𝗽𝗹𝗶𝗳𝘆 𝗬𝗼𝘂𝗿 𝗚𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴 𝗪𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝘄𝗶𝘁𝗵 𝗘𝗹𝘂𝗚𝗲𝗻! 👍 Discover the 𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗼𝗳 𝗘𝗹𝘂𝗚𝗲𝗻, Eckert & Ziegler’s innovative 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗲𝗹𝘂𝘁𝗶𝗼𝗻 tool for 𝗴𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿𝘀. ⚙️ In our 𝘀𝘁𝗲𝗽-𝗯𝘆-𝘀𝘁𝗲𝗽 𝗶𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝘃𝗶𝗱𝗲𝗼, you’ll learn: ✅ How to 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀𝗹𝘆 𝗶𝗻𝘀𝘁𝗮𝗹𝗹 EluGen with your generator ✅ How to 𝗮𝗱𝗷𝘂𝘀𝘁 𝗲𝗹𝘂𝘁𝗶𝗼𝗻 𝗽𝗮𝗿𝗮𝗺𝗲𝘁𝗲𝗿𝘀 with the intuitive touch panel ✅ How to 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗲𝗹𝘂𝘁𝗶𝗼𝗻𝘀 and pre-elutions ✅ How to leverage advanced features like the 𝘁𝗶𝗺𝗲𝗿 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗱𝗲𝗹𝗮𝘆𝗲𝗱 𝘀𝘁𝗮𝗿𝘁𝘀 Whether you’re a 𝘀𝗲𝗮𝘀𝗼𝗻𝗲𝗱 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹 𝗼𝗿 𝗻𝗲𝘄 𝘁𝗼 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻, EluGen is designed to 𝘀𝗶𝗺𝗽𝗹𝗶𝗳𝘆 your workflows, 𝗲𝗻𝗵𝗮𝗻𝗰𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 in daily routine and support your 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻. 🚀 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝘃𝗶𝗱𝗲𝗼 𝗻𝗼𝘄 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗵𝗼𝘄! 🧠 Want to re-watch it later? Find it on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 @𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮! 🎥 💬If you'd like to 𝗸𝗻𝗼𝘄 𝗺𝗼𝗿𝗲 about EluGen, just 𝗹𝗲𝗮𝘃𝗲 𝘂𝘀 𝗮 𝗰𝗼𝗺𝗺𝗲𝗻𝘁 down below 🔽 #NuclearMedicine #Radiopharmaceuticals #MolecularImaging #Gallium #ContributingToSavingLives  

🌏 𝗘𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝗮𝗰𝗵: 𝗚𝗮𝗹𝗹𝗶𝗮𝗣𝗵𝗮𝗿𝗺® 𝗦𝘂𝗯𝗺𝗶𝘁𝘁𝗲𝗱 𝗳𝗼𝗿 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗶𝗻 𝗝𝗮𝗽𝗮𝗻! ✅ Eckert & Ziegler has officially 𝘀𝘂𝗯𝗺𝗶𝘁𝘁𝗲𝗱 𝗚𝗮𝗹𝗹𝗶𝗮𝗣𝗵𝗮𝗿𝗺®, our 68Ge/68Ga Radionuclide Generator, for 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗯𝘆 𝗝𝗮𝗽𝗮𝗻’𝘀 𝗠𝗶𝗻𝗶𝘀𝘁𝗿𝘆 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵, 𝗟𝗮𝗯𝗼𝘂𝗿 𝗮𝗻𝗱 𝗪𝗲𝗹𝗳𝗮𝗿𝗲 (MHLW). This milestone is set to bring cutting-edge 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝘁𝗼𝗼𝗹𝘀 like 68Ga-PSMA-11 𝗰𝗹𝗼𝘀𝗲𝗿 𝘁𝗼 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗮𝗻𝗱 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in Japan. 𝗔 𝗯𝗶𝗴 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to Novartis Japan (Novartis Pharma K.K.), our trusted partner in managing safety information and 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗶𝗻 𝗝𝗮𝗽𝗮𝗻. 🙏 GalliaPharm®, our 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗴𝗮𝗹𝗹𝗶𝘂𝗺 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿, plays an important role in 𝗽𝗼𝘀𝗶𝘁𝗿𝗼𝗻 𝗲𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝘁𝗼𝗺𝗼𝗴𝗿𝗮𝗽𝗵𝘆 (𝗣𝗘𝗧) 𝗶𝗺𝗮𝗴𝗶𝗻𝗴, particularly in oncology for 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 using PSMA imaging. With approval in Japan, we aim to 𝗲𝗺𝗽𝗼𝘄𝗲𝗿 𝘁𝗵𝗲 𝗹𝗼𝗰𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 with reliable tools to 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗲𝗮𝗿𝗹𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 and improve patient outcomes. 💙 💬 𝗗𝗿. Deljana Werner, Head of QA and Regulatory Affairs, shared: “As a company 𝗰𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆, GalliaPharm®’s entry into the Japanese market represents a pivotal opportunity to 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝗶𝗻 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲 through precise and innovative imaging solutions.” This submission underscores Eckert & Ziegler SE’s dedication to 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗱𝗶𝘃𝗲𝗿𝘀𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗺𝗮𝗿𝗸𝗲𝘁𝘀 and delivering innovative nuclear medicine solutions worldwide. 🔗 For more information, check out the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄 🔽 #NuclearMedicine #Radiopharmaceuticals #MolecularImaging #ContributingToSavingLives  

𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗥𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻: 𝟭𝟱 𝗬𝗲𝗮𝗿𝘀 𝗼𝗳 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 💡 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗮𝗻𝗱 𝘀𝗮𝗳𝗲𝘁𝘆 are at the core of 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻, and Eckert & Ziegler is leading the way. With our 𝘀𝘁𝗲𝗿𝗶𝗹𝗲 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 𝗰𝗮𝘀𝘀𝗲𝘁𝘁𝗲𝘀, designed for seamless 𝗚𝗠𝗣-𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀, we’ve set a new standard in radiochemistry. ⚛️ Discover how our technology and 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 are helping 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝘀, 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲𝘀, 𝗮𝗻𝗱 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 worldwide produce radiopharmaceuticals 𝗳𝗮𝘀𝘁𝗲𝗿 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆 than ever. From cleanroom innovation to rigorous quality control, we’re 𝗿𝗮𝗶𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗯𝗮𝗿 𝗳𝗼𝗿 𝗰𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲𝗱 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝘆. ⚙️ 👁️ 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴 𝘁𝗼: ▶️ Explore our 𝘀𝘁𝗮𝘁𝗲-𝗼𝗳-𝘁𝗵𝗲-𝗮𝗿𝘁 𝗰𝗮𝘀𝘀𝗲𝘁𝘁𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 process for Modular-Lab and beyond ▶️ Learn about the milestones behind 𝟱𝟬+ 𝗰𝗮𝘀𝘀𝗲𝘁𝘁𝗲 𝘁𝘆𝗽𝗲𝘀 𝗮𝗻𝗱 𝟮𝟬𝟬+ 𝗱𝗲𝘀𝗶𝗴𝗻𝘀 ▶️ Understand how we ensure 𝗺𝗮𝘅𝗶𝗺𝘂𝗺 𝘀𝘁𝗲𝗿𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝗰𝗲 👉 𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝘁𝗵𝗲 𝗹𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝘁𝗼 𝗱𝗶𝘃𝗲 𝗶𝗻 🔽 #Radiochemistry #Radiopharmaceuticals #NuclearMedicine #GMP #ContributingToSavingLives  

🌟𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄 𝗚𝗿𝗼𝘂𝗻𝗱 𝗶𝗻 𝗔𝗹𝗽𝗵𝗮 𝗥𝗮𝗱𝗶𝗼𝗰𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 🙌 We are thrilled to share the 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 of the innovative paper, "𝗟𝗲𝗮𝗱-𝗶𝘁-𝗘𝗔𝗭𝗬!", authored by the team led by Dr. Marc Pretze at the Universitätsklinikum Carl Gustav Carus Dresden. This research highlights the 𝗚𝗠𝗣-𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 [𝟮𝟭𝟮𝗣𝗯]𝗣𝗯-𝗣𝗦𝗖-𝗣𝗘𝗚𝟮-𝗧𝗢𝗖 𝘂𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗠𝗼𝗱𝘂𝗹𝗮𝗿-𝗟𝗮𝗯 𝗲𝗮𝘇𝘆 radiosynthesizer, showcasing the potential for 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱, 𝘀𝗰𝗮𝗹𝗮𝗯𝗹𝗲 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗮𝗹𝗽𝗵𝗮 𝘁𝗵𝗲𝗿𝗮𝗽𝘆. ⚙️ This achievement in 212Pb radiochemistry builds on 𝗗𝗿. 𝗣𝗿𝗲𝘁𝘇𝗲’𝘀 𝗽𝗿𝗲𝘃𝗶𝗼𝘂𝘀 𝘄𝗼𝗿𝗸 𝗶𝗻 𝗔𝗰-𝟮𝟮𝟱 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝗹𝗮𝗯𝗲𝗹𝗶𝗻𝗴 𝗼𝗻 𝗠𝗟 𝗲𝗮𝘇𝘆, underlining our shared commitment to advancing radiopharmaceutical innovation. 🚀 At Eckert & Ziegler SE, we are proud to support such cutting-edge research. This milestone exemplifies our dedication to being at the 𝗳𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝗮𝗹𝗽𝗵𝗮 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 through: ✅ 𝗥𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗿𝗮𝗱𝗶𝗼𝗻𝘂𝗰𝗹𝗶𝗱𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 for development and clinical application of next-gen diagnostic tools and radiotherapeutics ⚛️ ✅ 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝗿𝗮𝗱𝗶𝗼𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 𝗲𝗾𝘂𝗶𝗽𝗺𝗲𝗻𝘁 for versatile radiochemistry applications in GMP environments 🥼 ✅ 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 to ensure the safety of your radiopharmaceuticals 🔬 🤝 𝗔 𝗯𝗶𝗴 𝘁𝗵𝗮𝗻𝗸-𝘆𝗼𝘂 𝘁𝗼 𝗗𝗿. 𝗣𝗿𝗲𝘁𝘇𝗲 𝗮𝗻𝗱 𝗵𝗶𝘀 𝘁𝗮𝗹𝗲𝗻𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 for their close cooperation and contributions to shaping the future of targeted therapies. Together, we continue to push the boundaries of innovation for the 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲. 💙 🔗 𝗖𝘂𝗿𝗶𝗼𝘂𝘀 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? Check out the paper by following the 𝗹𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 🔽 #AlphaTherapy #Radiopharmaceuticals #NuclearMedicine #Radiochemistry #ContributingToSavingLives  

📣 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝘄𝗶𝗹𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 Ariceum Therapeutics 𝘄𝗶𝘁𝗵 𝗔𝗰-𝟮𝟮𝟱 𝗮𝗻𝗱 𝗟𝘂-𝟭𝟳𝟳 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝘁𝗵𝗲𝗶𝗿 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻 𝗿𝗮𝗱𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 ⚛️ We’re heading into an 𝗲𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 with Ariceum Therapeutics, a biotech innovator in radiopharmaceuticals, to 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗵𝗮𝗿𝗱-𝘁𝗼-𝘁𝗿𝗲𝗮𝘁 𝗰𝗮𝗻𝗰𝗲𝗿𝘀. Under this agreement, 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝘄𝗶𝗹𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 non-carrier-added 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (𝗔𝗰-𝟮𝟮𝟱) 𝗮𝗻𝗱 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 (𝗟𝘂-𝟭𝟳𝟳) for the radiolabeling of 𝗔𝗿𝗶𝗰𝗲𝘂𝗺’𝘀 𝗹𝗲𝗮𝗱 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲, 𝘀𝗮𝘁𝗼𝗿𝗲𝗼𝘁𝗶𝗱𝗲. This first-in-class radiopharmaceutical will soon enter clinical development for 𝘀𝗺𝗮𝗹𝗹 𝗰𝗲𝗹𝗹 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝗻𝗱 𝗠𝗲𝗿𝗸𝗲𝗹 𝗖𝗲𝗹𝗹 𝗖𝗮𝗿𝗰𝗶𝗻𝗼𝗺𝗮. This partnership represents: ✅ A 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 of high-quality therapeutic radioisotopes ✅ A major step toward 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲𝘀 of Ac-225 and Lu-177 ✅ 𝗔 𝗯𝗼𝗼𝘀𝘁 𝗳𝗼𝗿 𝗔𝗿𝗶𝗰𝗲𝘂𝗺'𝘀 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 and future commercialization activities 💬 Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, highlights: “Both the 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝘀𝘁𝗮𝗿𝘁 𝗳𝗼𝗿 𝗔𝗰-𝟮𝟮𝟱, announced earlier this week, and the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗼𝗳 𝗧𝗵𝗲𝗿𝗮𝗹𝘂𝗴𝗮𝗻𝗱®, show that our goal is to 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲 𝘁𝗵𝗲 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲 of high-quality radioisotopes. We aim to 𝗳𝗼𝘀𝘁𝗲𝗿 𝘁𝗵𝗲 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗼𝗳 𝗻𝗼𝘃𝗲𝗹 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 in clinical trials and beyond, and thus 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲 𝘁𝗼 𝘀𝗮𝘃𝗶𝗻𝗴 𝗹𝗶𝘃𝗲𝘀.” 💬 𝗗𝗿. Manfred Ruediger, CEO of 𝗔𝗿𝗶𝗰𝗲𝘂𝗺 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, adds: “We are 𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿𝘄𝗮𝗿𝗱 𝘁𝗼 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝘁𝗲𝗮𝗺 to build a robust supply chain and to 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝘆 𝗱𝗲𝗹𝗶𝘃𝗲𝗿 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 for patients with hard-to-treat cancers.” We’re proud to play a 𝘃𝗶𝘁𝗮𝗹 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝘁𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 that may revolutionize cancer care and 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲. 💙 🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 - 𝗟𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 𝗯𝗲𝗹𝗼𝘄 🔽 #Radiopharmaceuticals #NuclearMedicine #RadioligandTherapy #Theranostics #ContributingToSavingLives  

𝗠𝗮𝘅𝗶𝗺𝗶𝘇𝗲 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 with the 𝗠𝘂𝗹𝘁𝗶 𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿 𝗘𝗹𝘂𝘁𝗶𝗼𝗻 𝗧𝗼𝗼𝗹 and work with up to 𝘁𝗵𝗿𝗲𝗲 𝗴𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿𝘀 in parallel! 🚀 As the 𝗱𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗴𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴-𝗯𝗮𝘀𝗲𝗱 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗶𝗺𝗮𝗴𝗶𝗻𝗴 continues to grow, so does the need for 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝘀𝗮𝗳𝗲𝗿, 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 in radiolabeling processes. Eckert & Ziegler's Multi Generator Elution Tool rises to the challenge with 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 🙌 ✅ 𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗲𝗹𝘂𝘁𝗶𝗼𝗻 of up to 𝟯 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿𝘀 for a single production process ✅ 𝗦𝘁𝗮𝗻𝗱-𝗮𝗹𝗼𝗻𝗲 𝘂𝘀𝗲 or seamless integration with our 𝗠𝗼𝗱𝘂𝗹𝗮𝗿-𝗟𝗮𝗯 𝗲𝗮𝘇𝘆 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗧𝗿𝗮𝗰𝗲𝗿 radiosynthesizers ✅ Flexibility to use 𝗹𝗼𝘄 𝗮𝗻𝗱 𝗵𝗶𝗴𝗵 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝗶𝗲𝘀 for tailored workflows ✅ 𝗘𝘅𝘁𝗲𝗻𝗱𝗲𝗱 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿 𝗹𝗶𝗳𝗲𝘀𝗽𝗮𝗻 by combining eluates ✅ 𝗛𝗶𝗴𝗵 𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆 𝘁𝗿𝗮𝗰𝗲𝗿𝘀 made efficiently in just one process The tool is fully integrated with our 𝗥𝗮𝗣𝗘𝗧-𝗟𝗮𝗯 𝗪𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲, ensuring a streamlined and 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗳𝗿𝗼𝗺 𝗲𝗹𝘂𝘁𝗶𝗼𝗻 𝘁𝗼 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗰𝗼𝗻𝘁𝗿𝗼𝗹. Designed specifically for Eckert & Ziegler’s Modular-Lab product line, it offers an 𝘂𝗻𝗺𝗮𝘁𝗰𝗵𝗲𝗱 𝘀𝘆𝗻𝗲𝗿𝗴𝘆 between hardware and software for 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗿𝗲𝗹𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆.  🎯 Through the combination of 𝘂𝗽 𝘁𝗼 𝘁𝗵𝗿𝗲𝗲 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗼𝗿𝘀, our Multi Generator Elution Tool offers 𝘂𝗻𝗽𝗮𝗿𝗮𝗹𝗹𝗲𝗹𝗲𝗱 𝗰𝗮𝗽𝗮𝗰𝗶𝘁𝘆 𝗮𝗻𝗱 𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗹𝗶𝘁𝘆, setting a new standard in radiolabeling. With 𝗮𝗹𝗺𝗼𝘀𝘁 𝗮 𝗱𝗲𝗰𝗮𝗱𝗲 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘂𝘀𝗲, the tool is well established and 𝗱𝗼𝘇𝗲𝗻𝘀 𝗼𝗳 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀 are already using the system to take their 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝘆 𝘁𝗼 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗹𝗲𝘃𝗲𝗹. 🔝 🔗 𝗪𝗮𝗻𝘁 𝘁𝗼 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲? Check out the 𝗹𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 below and 𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 𝘁𝗼𝗱𝗮𝘆 to discuss how this tool can elevate your production capabilities. 📈 #Radiochemistry #Radiopharmaceuticals #NuclearMedicine #Gallium68 #ContributingToSavingLives  

𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗕𝗲𝗴𝗶𝗻𝘀 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 🚀 Today, we celebrate the successful c𝗼𝗺𝗺𝗲𝗻𝗰𝗲𝗺𝗲𝗻𝘁 𝗼𝗳 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (𝗔𝗰-𝟮𝟮𝟱) 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 together with our partners at the Nuclear Physics Institute CAS. 🎉 🔬 𝗧𝗵𝗲 𝗜𝗺𝗽𝗮𝗰𝘁 This milestone of our 𝗰𝗼𝗺𝗺𝗼𝗻 𝗽𝗿𝗼𝗷𝗲𝗰𝘁 addresses a 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝗵𝗼𝗿𝘁𝗮𝗴𝗲 of this critical radionuclide. Ac-225 is vital for developing 𝗮𝗹𝗽𝗵𝗮-𝗲𝗺𝗶𝘁𝘁𝗶𝗻𝗴 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀, a promising approach in targeted cancer therapies. Our 𝗰𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻-𝗯𝗮𝘀𝗲𝗱 production of 𝗔𝗰-𝟮𝟮𝟱 𝗳𝗿𝗼𝗺 𝗥𝗮𝗱𝗶𝘂𝗺-𝟮𝟮𝟲 is a pivotal advancement, ensuring reliability and scalability for 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. 💡 𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘅𝘁? We’ve initiated validation processes for 𝗚𝗠𝗣-𝗴𝗿𝗮𝗱𝗲 𝗔𝗰-𝟮𝟮𝟱, expected to be available in the 𝗳𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳 𝗼𝗳 𝟮𝟬𝟮𝟱. This breakthrough will unlock 𝗻𝗲𝘄 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗳𝗼𝗿 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 and support the development of potentially 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀. 🤝 𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗯𝘆 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 This achievement was made possible through our 𝘀𝘁𝗿𝗼𝗻𝗴 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗡𝘂𝗰𝗹𝗲𝗮𝗿 𝗣𝗵𝘆𝘀𝗶𝗰𝘀 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗖𝘇𝗲𝗰𝗵 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 (ÚJF) and the 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 of the team at Eckert & Ziegler Hot Cells. With this success, Eckert & Ziegler continues to 𝗹𝗲𝗮𝗱 𝘁𝗵𝗲 𝘄𝗮𝘆 𝗶𝗻 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, ensuring a 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗶𝘀𝗼𝘁𝗼𝗽𝗲𝘀 for a brighter future in nuclear medicine 🔗 Read the 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 for more details — 𝗟𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 ⬇️ #Actinium225 #NuclearMedicine #Radiopharmaceuticals #AlphaTherapy #ContributingToSavingLives  

📣 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀: 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗔𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗧𝗵𝗲𝗿𝗮𝗹𝘂𝗴𝗮𝗻𝗱® - 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 𝗖𝗵𝗹𝗼𝗿𝗶𝗱𝗲 (𝗻.𝗰.𝗮) 🙌 Today, Eckert & Ziegler SE's proprietary Theralugand® has 𝗿𝗲𝗰𝗲𝗶𝘃𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 from the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗖𝗼𝗺𝗺𝗶𝘀𝘀𝗶𝗼𝗻! 🎉 This milestone marks a new era for our non-carrier added Lutetium-177 chloride, which is now 𝗿𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗿𝗼𝘂𝘁𝗶𝗻𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 across the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗔𝗿𝗲𝗮 (EEA). 🌍 Theralugand® offers 𝗵𝗶𝗴𝗵-𝗽𝘂𝗿𝗶𝘁𝘆, 𝗚𝗠𝗣-𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳 designed for the labeling of radiopharmaceuticals, enabling innovative therapies for conditions like neuroendocrine tumors and metastatic prostate cancer. 𝗣𝗿𝗲𝘃𝗶𝗼𝘂𝘀𝗹𝘆 𝗹𝗶𝗺𝗶𝘁𝗲𝗱 𝘁𝗼 𝗶𝗻𝘃𝗲𝘀𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘂𝘀𝗲, Theralugand® can now support 𝗿𝗼𝘂𝘁𝗶𝗻𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀. 🏥 Through 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝘄𝗶𝘁𝗵 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 worldwide, Eckert & Ziegler is advancing targeted radiotherapies, addressing the 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗱𝗲𝗺𝗮𝗻𝗱 for reliable therapeutic radioisotopes. 📈 💬 Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, shares: “We are excited to achieve the 𝗘𝗖 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗧𝗵𝗲𝗿𝗮𝗹𝘂𝗴𝗮𝗻𝗱®, a critical step in making innovative treatment options 𝘄𝗶𝗱𝗲𝗹𝘆 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗳𝗼𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝘂𝗿𝗼𝗽𝗲. This accomplishment reflects our 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗼𝗳 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀.” We’re 𝗿𝗮𝗺𝗽𝗶𝗻𝗴 𝘂𝗽 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 to ensure a 𝘀𝘁𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳, contributing to the continued evolution of cancer care globally. 🚀 Read the full press release - Link in the comments below ⬇️ #NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Lutetium #ContributingToSavingLives  

It was an honor to welcome distinguished 𝘃𝗶𝘀𝗶𝘁𝗼𝗿𝘀 𝗳𝗿𝗼𝗺 𝗕𝗲𝗿𝗹𝗶𝗻 to our 𝗕𝗼𝘀𝘁𝗼𝗻 𝗔𝗿𝗲𝗮 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝘀𝗶𝘁𝗲! 👋 Yesterday, Eckert & Ziegler SE in Wilmington, MA had the pleasure of hosting 𝗙𝗿𝗮𝗻𝘇𝗶𝘀𝗸𝗮 𝗚𝗶𝗳𝗳𝗲𝘆, Berlin’s 𝗦𝗲𝗻𝗮𝘁𝗼𝗿 𝗳𝗼𝗿 𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗔𝗳𝗳𝗮𝗶𝗿𝘀 and 𝗗𝗿. 𝗛𝗲𝗻𝗿𝘆 𝗠𝗮𝗿𝘅, 𝗕𝗲𝗿𝗹𝗶𝗻 𝗦𝗲𝗰𝗿𝗲𝘁𝗮𝗿𝘆 𝗼𝗳 𝗦𝘁𝗮𝘁𝗲 𝗳𝗼𝗿 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 along with their teams. They were joined by esteemed members of the 𝗕𝗲𝗿𝗹𝗶𝗻 𝗖𝗵𝗮𝗺𝗯𝗲𝗿 𝗼𝗳 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗲 𝗮𝗻𝗱 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 (IHK Berlin), including 𝗝𝗮𝗻 𝗘𝗱𝗲𝗿, Sonja Jost, and Lars Mölbitz. Their tour of our 𝘀𝘁𝗮𝘁𝗲-𝗼𝗳-𝘁𝗵𝗲-𝗮𝗿𝘁 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 facility near Boston offered a glimpse into the 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 and 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 in nuclear medicine and radiochemistry. “Our site is not only a 𝗵𝘂𝗯 𝗳𝗼𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝗮𝗻𝗱 𝘀𝘂𝗽𝗽𝗹𝘆𝗶𝗻𝗴 𝗲𝘀𝘀𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝘀𝗼𝘁𝗼𝗽𝗲𝘀 like 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳, 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱, 𝗚𝗮𝗹𝗹𝗶𝘂𝗺-𝟲𝟴, 𝗬𝘁𝘁𝗿𝗶𝘂𝗺-𝟵𝟬 𝗮𝗻𝗱 𝗟𝗲𝗮𝗱-𝟮𝟬𝟯. With our advanced 𝗚𝗠𝗣 𝗦𝘂𝗶𝘁𝗲𝘀, we are also positioned to deliver 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘂𝗽𝗽𝗹𝗶𝗲𝘀 of radiopharmaceuticals directly to the North American market and beyond,” said Jay Simon, Managing Director for Eckert & Ziegler in the US, “This capability underlines our commitment to 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗯𝗼𝘁𝗵 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 in pioneering advancements that 𝗲𝗻𝗵𝗮𝗻𝗰𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲 𝘄𝗼𝗿𝗹𝗱𝘄𝗶𝗱𝗲.” At Eckert & Ziegler, we’re proud to share how our 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 are not only fueling cutting-edge innovations in cancer diagnosis and treatment, but also 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝘁𝗼 𝗼𝘂𝗿 𝗕𝗲𝗿𝗹𝗶𝗻 𝗴𝘂𝗲𝘀𝘁𝘀 for visiting and for the 𝗲𝗻𝗴𝗮𝗴𝗶𝗻𝗴 𝗱𝗶𝗮𝗹𝗼𝗴𝘂𝗲𝘀 on the future of radiopharmaceuticals and 𝗰𝗿𝗼𝘀𝘀-𝗯𝗼𝗿𝗱𝗲𝗿 𝗰𝗼𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗼𝘂𝗿 𝗳𝗶𝗲𝗹𝗱! #NuclearMedicine #Radiopharmaceuticals #PrecisionMedicine  #ContributingToSavingLives